Breast Cancer

Increased risk for all-cause mortality seen with postpartum young-onset breast cancer in women with germline BRCA pathogenic variants Young-onset breast cancer (YOBC) with germline BRCA pathogenic variants (PVs) is associated with an increased risk for all-cause mortality if diagnosed within 10 years after childbirth, according to a study published online April 19 in JAMA Network Open. Zhenzhen Zhang,...

Salvianolic acid A, an anti-cancer agent, showed a potential effect on M2 tumor-associated macrophages in a cell culture study, which concluded that it may be useful for reprogramming these macrophages in the management of triple-negative breast cancer. Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with challenging management and a poor prognosis....

Findings seen among poor surgical candidates, with recurrence risk of 10 percent seen at 16 months Cryoablation can be performed effectively in nonsurgical breast cancer patients with varying tumors, according to a study presented at the annual meeting of the Society of Interventional Radiology, held from March 23 to 28 in Salt Lake City. Jolie...

In the IDEA trial, postmenopausal patients aged 50–69 years with pT1N0 unifocal invasive breast cancer who did not receive radiotherapy achieved a high level of disease control after 5 years. For over three decades, radiotherapy has been an essential part of the treatment following breast-conserving surgery (BCS) for patients with early-stage breast cancer. Recent studies...

Low-dose acetylsalicylic acid reduces inflammatory protein levels and tissue perfusion in dense breast tissue in postmenopausal women, according to the results of a new phase II clinical trial. High mammographic density is a major risk factor for breast cancer, contributing to approximately 30% of all breast cancer. There is a lack of research regarding the...

DRL-Trastuzumab was found to have similar efficacy, safety, pharmacokinetics, and immunogenicity as Herceptin in HER2-positive breast cancer patients in a randomized, double-blind study. Trastuzumab, marketed under the brand name Herceptin, is a standard therapy for human epidermal growth factor receptor 2 (HER2)-positive breast cancer. The drug DRL_TZ, a potential trastuzumab biosimilar to Herceptin, was developed...

The phase 2 DAISY trial confirms that T-DXd efficacy depends on HER2 expression in breast cancer cases. However, it shows that T-DXd also has moderate activity in HER2-non-expressing patients, suggesting an alternative mechanism of action. Breast cancer is among the five most common causes of cancer mortality. Despite improvements in its treatment, 5-year survival rates...

Trastuzumab deruxtecan shows robust efficacy, durable clinical benefit, and safety consistent with the known profile in human epidermal growth factor receptor 2-expressing tumors in a phase II study. Trastuzumab deruxtecan (T-DXd), a human epidermal growth factor receptor 2 (HER2)-directed antibody-drug conjugate, is currently approved for treating HER2-expressing breast and gastric cancers and HER2-mutant non-small cell...

A systematic review explores the promising connection between ferroptosis, a form of regulated cell death, and triple-negative breast cancer, offering new insights into prognosis and treatment strategies. By identifying potential biomarkers and therapeutic targets related to ferroptosis, this research opens avenues for personalized treatment approaches to this form of breast cancer known for its aggressive...